Quote:
Chairman Chris Swann, said: “On behalf of the Board, I would like to thank Colin for the significant contribution he has made in bringing the Company to the point where it is today with its first cancer diagnostic system, Cxbladder, acclaimed by clinicians in the United States and other markets as leading technology in the accurate diagnosis of bladder cancer.
“Pacific Edge is now successfully commercialising the Cxbladder technology in the world’s largest health market, the US, and looking to further developments of the Cxbladder system. In line with this, the Board has identified a number of commercialisation skills and capabilities that would be of value to the Company. We are in discussions with several candidates and we hope to make an announcement on appointment of new directors in the near future.”